Novel targeted therapies for advanced non-small lung cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, often diagnosed at advanced, incurable stages.
• Historically, advanced NSCLC had a poor 5-year survival rate of approximately 5%.
• Recent breakthroughs in understanding NSCLC's genetic underpinnings have revolutionized treatment approaches.

Purpose of the Study:

• To review recent advancements in novel targeted therapies for non-small cell lung cancer.
• To highlight the impact of targeted therapy on survival rates in advanced NSCLC.
• To provide an overview of newly approved agents and ongoing clinical trials.

Main Methods:

• Literature review of recent scientific publications and clinical trial data.
• Analysis of United States Food and Drug Administration (FDA) approvals for NSCLC targeted therapies.
• Synthesis of information on genetic mutations, biomarkers, and their role in treatment selection.

Main Results:

• Targeted therapies and immunotherapies have markedly improved the 5-year overall survival for advanced NSCLC patients.
• Survival rates now range from 15% to 50%, contingent upon specific mutations and biomarkers.
• The FDA has approved nearly 20 new targeted therapy agents in the last decade, with more under investigation.

Conclusions:

• Advances in understanding NSCLC genetics have led to effective targeted therapies.
• Targeted therapies represent a significant improvement over historical survival rates for advanced NSCLC.
• Ongoing research and clinical trials continue to expand the armamentarium of novel targeted agents for NSCLC treatment.